Use of metformin following a population-level intervention to encourage people with pre-diabetes to enroll in the National Diabetes Prevention Program
Open Access
- 13 October 2021
- journal article
- research article
- Published by BMJ in BMJ Open Diabetes Research & Care
- Vol. 9 (1), e002468
- https://doi.org/10.1136/bmjdrc-2021-002468
Abstract
Introduction The National Diabetes Prevention Program (NDPP) and metformin are interventions to slow progression from pre-diabetes to type 2 diabetes. When coverage for the NDPP was offered by a public research university’s health insurance plan, proactive strategies were used to combat historically low enrollment. Although not specifically targeted by these strategies, metformin use was higher than expected, leading to this evaluation. Research design and methods We used insurance enrollment, claims, pharmacy, and laboratory data for 64 131 adult employees, dependents, and retirees to identify individuals with pre-diabetes and invite them to enroll in the NDPP at no out-of-pocket cost. The characteristics of individuals with pre-diabetes who used metformin before and after their invitation were compared with NDPP enrollees. Results 8131 individuals with pre-diabetes were identified. Of these, 776 (9.5%) enrolled in a NDPP and 802 (9.9%) used metformin. Metformin users were younger, had higher body mass index, were more likely to have comorbidities, and had higher baseline hemoglobin A1c levels than non-users. Timing of metformin use varied with 107 (13%) discontinuing, 426 (53%) continuing, and 269 (34%) initiating metformin use after their NDPP invitation. Of NDPP enrollees, 13 (2%) discontinued, 56 (7%) continued, and 34 (4%) initiated metformin use when they enrolled. Conclusions Despite no active encouragement, use of metformin was similar to the rate of enrollment in the NDPP. Metformin use was higher for individuals with higher likelihood of responding. With the proven cost-effectiveness of metformin, targeted strategies to increase metformin use in individuals with pre-diabetes who are likely to respond, but not willing to enroll in a lifestyle intervention, are needed.Keywords
Funding Information
- National Institutes of Health (R01 DK109995)
This publication has 33 references indexed in Scilit:
- Screening for impaired fasting glucose and diabetes using available health plan dataJournal of Diabetes and its Complications, 2013
- The 10-Year Cost-Effectiveness of Lifestyle Intervention or Metformin for Diabetes PreventionDiabetes Care, 2012
- Diagnosis and Classification of Diabetes MellitusDiabetes Care, 2011
- 10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes StudyThe Lancet, 2009
- Sex Differences in Diabetes Risk and the Effect of Intensive Lifestyle Modification in the Diabetes Prevention ProgramDiabetes Care, 2008
- Weight Loss of Black, White, and Hispanic Men and Women in the Diabetes Prevention ProgramObesity, 2008
- The Indian Diabetes Prevention Programme shows that lifestyle modification and metformin prevent type 2 diabetes in Asian Indian subjects with impaired glucose tolerance (IDPP-1)Diabetologia, 2006
- The Effect of Metformin and Intensive Lifestyle Intervention on the Metabolic Syndrome: The Diabetes Prevention Program Randomized TrialAnnals of Internal Medicine, 2005
- Reduction in the Incidence of Type 2 Diabetes with Lifestyle Intervention or MetforminThe New England Journal of Medicine, 2002
- Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III)JAMA, 2001